Iverson Genetic Diagnostics to Sponsor the WARFARIN Study Designed to Address National Coverage and Safety Concerns of Warfarin (Coumadin(TM))

Published: Mar 15, 2010

ATLANTA--(BUSINESS WIRE)--Iverson Genetic Diagnostics, Inc. today announced that they will conduct a WARFARIN clinical study to assess the efficacy of gene-based testing prior to initiating warfarin anticoagulation therapy to reduce the incidence of bleeding and thromboembolic events. The multicenter, randomized, blinded, parallel-group study is being led by Principal Investigator Dr. Elizabeth Ofili, MD, Director of Clinical Research and Associate Dean for Clinical Research at Morehouse School of Medicine.

Back to news